221 related articles for article (PubMed ID: 33727089)
1. 4-Acetylantroquinonol B induced DNA damage response signaling and apoptosis via suppressing CDK2/CDK4 expression in triple negative breast cancer cells.
Satriyo PB; Su CM; Ong JR; Huang WC; Fong IH; Lin CC; Aryandono T; Haryana SM; Deng L; Huang CC; Tzeng YM; Chao TY; Liu HW; Yeh CT
Toxicol Appl Pharmacol; 2021 Jul; 422():115493. PubMed ID: 33727089
[TBL] [Abstract][Full Text] [Related]
2. 4-Acetylantroquinonol B inhibits colorectal cancer tumorigenesis and suppresses cancer stem-like phenotype.
Chang TC; Yeh CT; Adebayo BO; Lin YC; Deng L; Rao YK; Huang CC; Lee WH; Wu AT; Hsiao M; Wu CH; Wang LS; Tzeng YM
Toxicol Appl Pharmacol; 2015 Oct; 288(2):258-68. PubMed ID: 26235807
[TBL] [Abstract][Full Text] [Related]
3. 4-Acetylantroquinonol B suppresses autophagic flux and improves cisplatin sensitivity in highly aggressive epithelial cancer through the PI3K/Akt/mTOR/p70S6K signaling pathway.
Liu M; Bamodu OA; Huang WC; Zucha MA; Lin YK; Wu ATH; Huang CC; Lee WH; Yuan CC; Hsiao M; Deng L; Tzeng YM; Yeh CT
Toxicol Appl Pharmacol; 2017 Jun; 325():48-60. PubMed ID: 28408137
[TBL] [Abstract][Full Text] [Related]
4. Single-Cell Dynamics Determines Response to CDK4/6 Inhibition in Triple-Negative Breast Cancer.
Asghar US; Barr AR; Cutts R; Beaney M; Babina I; Sampath D; Giltnane J; Lacap JA; Crocker L; Young A; Pearson A; Herrera-Abreu MT; Bakal C; Turner NC
Clin Cancer Res; 2017 Sep; 23(18):5561-5572. PubMed ID: 28606920
[No Abstract] [Full Text] [Related]
5. Combined CDK4/6 and PI3Kα Inhibition Is Synergistic and Immunogenic in Triple-Negative Breast Cancer.
Teo ZL; Versaci S; Dushyanthen S; Caramia F; Savas P; Mintoff CP; Zethoven M; Virassamy B; Luen SJ; McArthur GA; Phillips WA; Darcy PK; Loi S
Cancer Res; 2017 Nov; 77(22):6340-6352. PubMed ID: 28947417
[TBL] [Abstract][Full Text] [Related]
6. Targeting cyclin-dependent kinase 1 (CDK1) but not CDK4/6 or CDK2 is selectively lethal to MYC-dependent human breast cancer cells.
Kang J; Sergio CM; Sutherland RL; Musgrove EA
BMC Cancer; 2014 Jan; 14():32. PubMed ID: 24444383
[TBL] [Abstract][Full Text] [Related]
7. RB expression confers sensitivity to CDK4/6 inhibitor-mediated radiosensitization across breast cancer subtypes.
Pesch AM; Hirsh NH; Michmerhuizen AR; Jungles KM; Wilder-Romans K; Chandler BC; Liu M; Lerner LM; Nino CA; Ward C; Cobain EF; Lawrence TS; Pierce LJ; Rae JM; Speers CW
JCI Insight; 2022 Feb; 7(3):. PubMed ID: 34932500
[TBL] [Abstract][Full Text] [Related]
8. Anti-tumor and anti-metastasis efficacy of E6201, a MEK1 inhibitor, in preclinical models of triple-negative breast cancer.
Lee J; Lim B; Pearson T; Choi K; Fuson JA; Bartholomeusz C; Paradiso LJ; Myers T; Tripathy D; Ueno NT
Breast Cancer Res Treat; 2019 Jun; 175(2):339-351. PubMed ID: 30826934
[TBL] [Abstract][Full Text] [Related]
9. Honokiol inhibits in vitro and in vivo growth of oral squamous cell carcinoma through induction of apoptosis, cell cycle arrest and autophagy.
Huang KJ; Kuo CH; Chen SH; Lin CY; Lee YR
J Cell Mol Med; 2018 Mar; 22(3):1894-1908. PubMed ID: 29363886
[TBL] [Abstract][Full Text] [Related]
10. Dual Inhibition of Key Proliferation Signaling Pathways in Triple-Negative Breast Cancer Cells by a Novel Derivative of Taiwanin A.
Kuo YH; Chiang EI; Chao CY; Rodriguez RL; Chou PY; Tsai SY; Pai MH; Tang FY
Mol Cancer Ther; 2017 Mar; 16(3):480-493. PubMed ID: 27956520
[TBL] [Abstract][Full Text] [Related]
11. Ribociclib (LEE011) suppresses cell proliferation and induces apoptosis of MDA-MB-231 by inhibiting CDK4/6-cyclin D-Rb-E2F pathway.
Li T; Xiong Y; Wang Q; Chen F; Zeng Y; Yu X; Wang Y; Zhou F; Zhou Y
Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):4001-4011. PubMed ID: 31588803
[TBL] [Abstract][Full Text] [Related]
12. Cyclin E Overexpression Sensitizes Triple-Negative Breast Cancer to Wee1 Kinase Inhibition.
Chen X; Low KH; Alexander A; Jiang Y; Karakas C; Hess KR; Carey JPW; Bui TN; Vijayaraghavan S; Evans KW; Yi M; Ellis DC; Cheung KL; Ellis IO; Fu S; Meric-Bernstam F; Hunt KK; Keyomarsi K
Clin Cancer Res; 2018 Dec; 24(24):6594-6610. PubMed ID: 30181387
[TBL] [Abstract][Full Text] [Related]
13. The antipsychotic agent trifluoperazine hydrochloride suppresses triple-negative breast cancer tumor growth and brain metastasis by inducing G0/G1 arrest and apoptosis.
Feng Z; Xia Y; Gao T; Xu F; Lei Q; Peng C; Yang Y; Xue Q; Hu X; Wang Q; Wang R; Ran Z; Zeng Z; Yang N; Xie Z; Yu L
Cell Death Dis; 2018 Sep; 9(10):1006. PubMed ID: 30258182
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of CDK-mediated Smad3 phosphorylation reduces the Pin1-Smad3 interaction and aggressiveness of triple negative breast cancer cells.
Thomas AL; Lind H; Hong A; Dokic D; Oppat K; Rosenthal E; Guo A; Thomas A; Hamden R; Jeruss JS
Cell Cycle; 2017 Aug; 16(15):1453-1464. PubMed ID: 28678584
[TBL] [Abstract][Full Text] [Related]
15. 4-Acetylantroquinonol B Inhibits Osteoclastogenesis by Inhibiting the Autophagy Pathway in a Simulated Microgravity Model.
Wu CH; Ou CH; Yen IC; Lee SY
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32971944
[TBL] [Abstract][Full Text] [Related]
16. Higher levels of TIMP-1 expression are associated with a poor prognosis in triple-negative breast cancer.
Cheng G; Fan X; Hao M; Wang J; Zhou X; Sun X
Mol Cancer; 2016 Apr; 15(1):30. PubMed ID: 27130446
[TBL] [Abstract][Full Text] [Related]
17. Differential Regulation of Cancer Progression by CDK4/6 Plays a Central Role in DNA Replication and Repair Pathways.
Dai M; Boudreault J; Wang N; Poulet S; Daliah G; Yan G; Moamer A; Burgos SA; Sabri S; Ali S; Lebrun JJ
Cancer Res; 2021 Mar; 81(5):1332-1346. PubMed ID: 33372040
[TBL] [Abstract][Full Text] [Related]
18. HSulf‑1 and palbociclib exert synergistic antitumor effects on RB‑positive triple‑negative breast cancer.
Chen F; Zhang Z; Yu Y; Liu Q; Pu F
Int J Oncol; 2020 Jul; 57(1):223-236. PubMed ID: 32377705
[TBL] [Abstract][Full Text] [Related]
19. Different mechanisms involved in the berberine-induced antiproliferation effects in triple-negative breast cancer cell lines.
Lin YS; Chiu YC; Tsai YH; Tsai YF; Wang JY; Tseng LM; Chiu JH
J Cell Biochem; 2019 Aug; 120(8):13531-13544. PubMed ID: 30957305
[TBL] [Abstract][Full Text] [Related]
20. Cross-species genomic and functional analyses identify a combination therapy using a CHK1 inhibitor and a ribonucleotide reductase inhibitor to treat triple-negative breast cancer.
Bennett CN; Tomlinson CC; Michalowski AM; Chu IM; Luger D; Mittereder LR; Aprelikova O; Shou J; Piwinica-Worms H; Caplen NJ; Hollingshead MG; Green JE
Breast Cancer Res; 2012 Jul; 14(4):R109. PubMed ID: 22812567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]